On this page
Executive Summary
Platelet-Rich Plasma (PRP) represents an increasingly explored autologous orthobiologic in the therapeutic landscape for osteoarthritis (OA). Derived from a patient's own blood through a centrifugation process, PRP delivers a concentrated solution of platelets and an array of bioactive growth factors, including platelet-derived growth factor (PDGF), transforming growth factor (TGF), insulin-like growth factor (IGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF). These components are believed to stimulate an immunological and inflammatory response that supports physiological healing, modulates inflammation, promotes tissue repair, and stimulates anabolic processes within chondrocytes, synoviocytes, and mesenchymal stem cells — with the overarching aim of alleviating pain and potentially slowing disease progression.
Current evidence suggests that PRP injections, particularly leukocyte-poor PRP (LP-PRP), can offer superior pain relief and functional improvement when compared to traditional treatments such as hyaluronic acid (HA) and corticosteroids. This benefit is most notable in patients with mild to moderate knee OA (Kellgren–Lawrence grades I–III). While some studies indicate sustained effects up to 12 months, the onset of pain relief with PRP may be slower than with corticosteroids. The effectiveness of PRP also varies significantly depending on the specific joint affected.
The safety profile of PRP is generally favourable, with reported adverse events typically mild and temporary, primarily consisting of post-injection pain. The autologous nature of PRP inherently minimises the risk of immune reactions or disease transmission.
Despite these promising outcomes, the clinical utility of PRP remains a subject of ongoing discussion. A primary challenge lies in the substantial variability of preparation protocols, including differences in platelet concentration, leukocyte content, and activation status. This heterogeneity complicates consistent conclusions and reproducibility across studies. Major clinical guidelines from organisations such as the AAOS, ACR, and OARSI maintain cautious or inconclusive stances, citing insufficient or low-quality evidence and concerns regarding study bias. Current imaging studies do not definitively demonstrate that PRP promotes cartilage regeneration or halts structural progression.
Introduction to Osteoarthritis and Platelet-Rich Plasma
Osteoarthritis is a pervasive and debilitating chronic degenerative joint disease that impacts millions globally. It is characterised by the progressive breakdown of articular cartilage, inflammation of the synovial membrane, and structural changes in the subchondral bone. Patients typically present with localised inflammation, persistent pain, joint stiffness, and restricted joint movement — collectively diminishing their capacity for daily activities and significantly reducing quality of life. The global burden of OA continues to escalate, driven by an aging population and rising rates of obesity.
Conventional management strategies for OA span a spectrum from conservative approaches — physical therapy, NSAIDs, and intra-articular injections (corticosteroids, hyaluronic acid) — to surgical interventions reserved for advanced stages. While these treatments aim to alleviate symptoms, they often provide only temporary relief, may be associated with side effects, or are considered only for severe, refractory cases. The limitations of these traditional methods have spurred interest in biological therapies that leverage the body's intrinsic healing capabilities.
PRP has emerged as a prominent example of such a biological treatment. It is autologous — derived directly from the patient's own blood — thereby minimising the risk of adverse immune reactions or disease transmission associated with allogeneic products. The preparation of PRP involves centrifuging a whole blood sample to achieve a concentration of platelets significantly higher than that found in whole blood.
The therapeutic rationale centres on the rich array of growth factors and cytokines released from activated platelets. These bioactive factors are believed to foster tissue repair and regeneration through several proposed mechanisms: stimulating angiogenesis, promoting cellular migration and proliferation (of chondrocytes, synoviocytes, and mesenchymal stem cells), and enhancing extracellular matrix deposition. PRP is also thought to modulate inflammatory and catabolic processes within the joint, shifting the joint environment towards an anabolic state.
Despite strong mechanistic plausibility, PRP's biological foundation has not consistently translated into definitive clinical proof of structural cartilage regeneration or disease modification. The RESTORE trial, for example, did not show significant differences in cartilage loss between PRP and placebo, indicating PRP does not halt structural progression of OA. This reframes PRP's current role as primarily symptomatic.
Clinical Efficacy of PRP in Osteoarthritis
The clinical efficacy of PRP in OA varies across different joints and depends on the duration of follow-up.
Knee osteoarthritis (KOA)
PRP injections — particularly leukocyte-poor PRP — have demonstrated superior pain relief and functional improvement compared to hyaluronic acid and corticosteroids in patients with mild to moderate KOA (Kellgren–Lawrence grades I–III). Retrospective analyses of large joint OA, including the knee, have reported clinically significant improvements in pain, with VAS scores improving by 49% at 6 months and 45% at 12 months. Functional outcomes, measured by SANE, showed improvements of 44% at 6 months and 39% at 12 months.
Multiple PRP injections have consistently been found more effective than a single injection for KOA, suggesting a cumulative benefit. Benefits typically last 6–12 months, with a reported success rate of 60–70% (defined as at least 50% improvement in pain and function).
Hip osteoarthritis (HOA)
Evidence for HOA is less consistent. A systematic review concluded that PRP injection therapy did not significantly reduce pain symptoms in patients with HOA compared to control groups — likely due to the hip joint's deeper cavity, reduced vascularity, and susceptibility to femoral head necrosis.
However, a more recent double-blind RCT (2019–2021) focusing on hip OA secondary to developmental dysplasia of the hip showed PRP was at least as effective as hyaluronic acid, with marginally higher pain-VAS improvement (38.5 for PRP vs. 18.7 for HA; P=.041) and significant WOMAC stiffness improvement at 24 weeks. A separate meta-analysis suggested combining PRP with HA for HOA may paradoxically worsen pain outcomes.
Shoulder & rotator cuff tendinopathy
While not strictly OA, studies on rotator cuff tendinopathy provide insight into PRP's effects on joint-related soft tissues. PRP significantly reduced pain and improved function in the short term (3–6 months) compared to both placebo and corticosteroids. Meta-analyses indicate PRP is a safe and effective intervention for long-term pain control and shoulder function in rotator cuff disorders, with significant differences in favour of PRP at 12 months post-intervention for pain.
Other joints
PRP injections have shown effectiveness in improving VAS pain scores in ankle osteoarthritis and temporomandibular joint OA. For lateral epicondylitis, PRP demonstrated superior early and mid-term outcomes compared to glucocorticoid and saline, with sustained pain reduction and better functional assessments.
The efficacy of PRP appears highly dependent on the specific joint, suggesting that anatomical factors — joint depth, vascularity, and mechanical loading — as well as the underlying pathology, significantly influence treatment success. This highlights the need for joint-specific research rather than generalising findings from one joint to another.
Comparative Effectiveness
PRP versus Hyaluronic Acid
For knee OA, PRP generally outperforms HA in most studies, with benefits often lasting 6–12 months compared to HA's typically shorter duration. A meta-analysis of 42 RCTs comparing HA and PRP for KOA found PRP resulted in significantly lower VAS and WOMAC scores. Multiple PRP injections produced an 80% reduction in VAS scores for KOA after 12 weeks, compared to 60% reduction with multiple HA injections.
For hip OA, evidence is more mixed — one study found PRP at least as effective as HA, while another meta-analysis suggested adding HA to PRP for hip OA may worsen pain outcomes.
PRP versus Corticosteroids
The comparison presents a nuanced picture — a trade-off between speed of onset and duration of effect. For knee OA, corticosteroids can produce better initial pain relief, particularly within the first 4–6 weeks. However, PRP typically outperforms corticosteroids at 3–6 months after treatment, providing more sustained improvements.
A 2025 prospective, double-blinded RCT for mild to moderate KOA found CS injections provided significantly greater pain reduction at 6 weeks, meeting MCID, while PRP did not. At 3 months, improvements were similar between groups. Conversely, a systematic review and meta-analysis concluded PRP was significantly better than CS in reducing KOA symptoms at 3, 6, and 9 months — with benefits up to 12 months.
Corticosteroids offer faster, acute pain relief while PRP — when effective — provides more sustained, slower-onset benefits. Repeated corticosteroid injections may have detrimental effects on articular cartilage, a risk not associated with PRP. For acute pain flare-ups, CS may be preferred. For chronic management aiming for durable effects without cartilage risk, PRP could be more suitable.
PRP versus placebo / saline
Meta-analyses of randomised controlled trials generally indicate PRP performs better than saline injections, particularly when longer-term results are analysed. For chronic tendinopathy across various anatomical sites, PRP significantly reduced pain at both 6 and 12 months.
Safety Profile
The safety profile of PRP is generally favourable. Reported adverse events are typically mild and temporary, primarily consisting of post-injection pain. The autologous nature of PRP inherently minimises the risk of immune reactions or disease transmission.
Common, transient side effects include:
- Mild swelling at the injection site lasting 8–24 hours
- Temporary increase in symptoms in the first 24–48 hours
- Tingling sensation during cell activation
- Very rarely, infection requiring antibiotic treatment
Mechanism of Action
PRP's proposed mechanisms include:
- Growth factor release — PDGF, TGF-β, IGF, FGF, and VEGF released from activated platelets
- Angiogenesis — stimulating formation of new blood vessels
- Cellular migration and proliferation — of chondrocytes, synoviocytes, and mesenchymal stem cells
- Extracellular matrix deposition — supporting tissue rebuilding
- Inflammatory modulation — shifting the joint environment from catabolic toward anabolic
Position of Clinical Guidelines
Major clinical guidelines from prominent organisations — the American Academy of Orthopaedic Surgeons (AAOS), American College of Rheumatology (ACR), and Osteoarthritis Research Society International (OARSI) — maintain cautious or inconclusive stances, citing insufficient or low-quality evidence and concerns regarding study bias. Current imaging studies do not definitively demonstrate PRP promotes cartilage regeneration or halts structural progression of OA.
A primary challenge is the substantial variability of preparation protocols across studies — differences in platelet concentration, leukocyte content, and activation status complicate consistent conclusions and reproducibility.
Cost-Effectiveness
The cost-effectiveness of PRP is complex. Some analyses suggest it may not be cost-effective from a broad societal perspective, largely due to lack of established efficacy in definitively delaying total knee arthroplasty. Other analyses indicate potential cost-effectiveness from a payer perspective if total treatment cost remains below certain thresholds over a 12-month period.
Conclusions
PRP represents a promising biological therapy in the OA treatment landscape, with meaningful evidence supporting its use particularly in mild to moderate knee osteoarthritis. Its favourable safety profile and absence of cartilage-damaging effects associated with repeated corticosteroid use make it an attractive option for chronic management.
However, significant challenges remain. The variability of PRP preparation protocols, lack of demonstrated structural disease modification, and cautious positions of major clinical guidelines all signal the need for further high-quality research with standardised methods. Joint-specific evidence — particularly distinguishing knee from hip outcomes — is essential for evidence-based clinical application.
For now, PRP's role appears primarily symptomatic but valuable, particularly when corticosteroid risk profiles preclude their continued use. Patient selection, joint specificity, and clear discussion of expectations regarding onset and duration of benefit remain central to good clinical practice.
This review is provided for educational purposes. It does not constitute individual medical advice. Patients should discuss treatment options with their treating doctor.